Navigation Links
ARIUS recognized for entrepreneurial excellence
Date:4/7/2008

Dr. David S. Young awarded "Most Innovative" award by the Association of

Chinese Canadian Entrepreneurs

TORONTO, April 7 /PRNewswire-FirstCall/ - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that Dr. David S. Young, President and Chief Executive Officer, received the "Most Innovative" award at the Chinese Canadian Entrepreneur Awards, held on April 5th, 2008 in Toronto, Ontario.

"The FunctionFIRST(TM) antibody discovery platform pioneered by our CEO is the foundation of our company and exemplifies the exceptional innovation that this award honours," said Warren Whitehead, Chief Financial Officer of ARIUS. "As we transition to a clinical company this year, we are proud that ARIUS' mission to generate and develop anti-cancer, antibody drugs has been recognized through this honour."

The Chinese Canadian Entrepreneur Awards, sponsored by the Association of Chinese Canadian Entrepreneurs (ACCE), annually recognizes high achievements by business people and entrepreneurs who have strengthened the competitiveness of Chinese Canadian business community in the global market. The Most Innovative Award is presented to an individual, team of individuals or company who have demonstrated exceptional innovation in their given field and contributed great value to the marketplace.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com.

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.


'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
2. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
3. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
4. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
5. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
6. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
7. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
10. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
11. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, ... strange place for a head lice treatment salon to set ... a Tuscan restaurant and a French bistro on E Madison ... "We aren,t just any old lice clinic, we pride ourselves ... comfortable, and release some of the stigma associated with lice. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs of ... Assay from Salimetrics’ SalivaLab , the relationship between insulin and other relevant ...
(Date:2/23/2017)... ... February 22, 2017 , ... ... , have been named Fellows of the Society this year, the Fellows Committee ... the multidisciplinary fields of optics, photonics, and imaging as well as their service ...
(Date:2/22/2017)... -- Scientists propose in Nature blocking a ... and maybe other lysosomal storage diseases as a possible ... therapies. An international research team led by ... included investigators from the University of Lübeck in ... The study was conducted in mouse models of lysosomal ...
Breaking Biology Technology:
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
Breaking Biology News(10 mins):